Pharmacogenetic analyses have implicated uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphisms in nilotinib-induced hyperbilirubinemia (Singer et al., 2007), consistent with previous reports of TKI-associated hepatotoxicity (Teo et al., 2013). The gene discussed is UGT1A1; the disease is Hyperbilirubinemia.